CD22, technical only
Use
CD22 antigen is expressed on both the cell membrane and in the cytoplasm of B-lymphocytes throughout the early stages of B-cell differentiation. Surface expression is variable and may be lost upon later stages of differentiation. CD22 has been reported to be strongly expressed in Hairy cell leukemia and weakly expressed in myeloid leukemias and non-T-cell acute lymphoblastic leukemias.
Special Instructions
Not provided.
Limitations
Specimens must be fixed in 10% neutral buffered formalin (NBF) or B plus. All other fixatives will be rejected. The stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Methodology
Immunoassay (IHC)
Biomarkers
CD22
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
FFPE Block, Formalin Fixed
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED).
Patient Preparation
Fresh Tissues: Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours.
Storage Instructions
15°C to 25°C
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinite |